INTRODUCTION
Glycosaminoglycans (GAGs) have been implicated in the regulation and maintenance of cell adhesion, cell proliferation, cytodifferentiation and tissue morphogenesis (reviewed in [1] [2] [3] ). In particular, crucial roles of GAGs, especially heparan sulphate, in developmental processes and signalling pathways of Wingless, Hedgehog and fibroblast growth factor in Drosophila have recently become evident [2] . The biological activities of GAGs depend on their ability to interact with various proteins including morphogens, growth factors, cytokines and extracellular matrix proteins through specific saccharide sequences embedded in GAG chains (reviewed in [4] ). Therefore the biosynthesis of GAGs is believed to be strictly regulated.
Sulphated GAGs, including heparin\heparan sulphate, chondroitin sulphate and dermatan sulphate, are covalently bound to serine residues in the core proteins through the common carbohydrate-protein linkage region structure, GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser [5] . Heparin\heparan sulphate is synthesized once GlcNAc has been transferred to the common linkage region, whereas chondroitin sulphate is formed if GalNAc is added first. The biosynthesis of these GAGs is initiated by the addition of a xylose residue to specific serine residues in the core protein and is followed by the addition of two galactose residues, a GlcA residue and then the alternate addition of N-acetylhexosamine and GlcA residues. The addition of each sugar is Abbreviations used : DAPI, 4,6-diamidino-2-phenylindole ; FISH, fluorescence in situ hybridization ; GAG, glycosaminoglycan ; GlcAT-I, glucuronyltransferase I (EC 2.4.1.135) ; GlcAT-P, glycoprotein-specific glucuronyltransferase [7] ; SV40, simian virus 40. 1 To whom correspondence should be addressed (e-mail kitagawa!kobepharma-u.ac.jp).
The nucleotide sequence data reported will appear in DDBJ, EMBL and GenBank2 Nucleotide Sequence Databases under the accession numbers AB047194 and AB049116.
transducers and activators of transcription). Screening of a human genomic library identified one additional distinct genomic clone containing an approx. 1.4 kb sequence region that shared an overall 95.3 % nucleotide identity with exons 1-5 of GlcAT-I. However, a lack of intron sequences, as well as the presence of several nucleotide mutations, insertions and deletions that disrupted the potential GlcAT-I reading frame, suggested that the clone contained a processed pseudogene. The pseudogene was localized to chromosome 3. The human genome therefore contains two related GlcAT-I genes that are located on separate chromosomes.
Key words : gene expression, gene structure, glycosaminoglycans, proteoglycan. thought to be catalysed by a specific glycosyltransferase, which uses the corresponding uridine diphosphate sugar as a donor substrate [5] .
The glucuronyl transfer to the galactose residue is catalysed by a β1,3-glucuronyltransferase termed glucuronyltransferase I (GlcAT-I), which transfers GlcA from UDP-GlcA to the trisaccharide-serine, Galβ1-3Galβ1-4Xylβ1-O-Ser, finalizing the formation of the common linkage region, GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser. We recently cloned the cDNA encoding the GlcAT-I from human placenta [6] on the basis of the information of the amino acid sequence alignment of rat glycoprotein-specific glucuronyltransferase (GlcAT-P) involved in the biosynthesis of the carbohydrate epitope HNK-1 with putative proteins in Caenorhabditis elegans and Schistosoma mansoni [7] . Interestingly, Bai et al. [8] showed that the transfection of Chinese hamster ovary cell mutants defective in GlcAT-I with GlcAT-I cDNA augmented GAG synthesis to levels approximately double that in wild-type cells, implying that GlcAT-I might be rate-limiting. In addition, the transfection of the GlcAT-I cDNA into COS-1 cells induced a significant expression of the HNK-1 epitope, suggesting that the high expression of GlcAT-I rendered the cells capable of synthesizing the HNK-1 epitope [9, 10] . It is therefore important to clarify the regulation of GlcAT-I expression.
In the present study we examined the structural organization and functional expression of human GlcAT-I. In addition, we identified a related processed pseudogene and localized GlcAT-I and the pseudogene to two distinct human chromosomes, 11q12-q13 and 3 respectively.
EXPERIMENTAL Cells
Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10 % (v\v) fetal bovine serum. The cell lines used were G361 human melanoma cells (A.T.C.C. CRL-1424), C32 human amelanotic melanoma cells (A.T.C.C. CRL-1585), HepG2 human hepatocellular carcinoma cells (A.T.C.C. HB-8065) and MFH-7 human malignant fibrous histiocytoma cells [11] .
Isolation of human GlcAT-I genomic clones
A human placenta genomic library in a λFIX II phage vector (Stratagene, La Jolla, CA, U.S.A.) was screened with the cloned human GlcAT-I cDNA fragment of 1.4 kb [6] . Three independent clones (C1-C3) were isolated and characterized. Insert DNA fragments were initially characterized by restriction digestion and Southern blot analysis. Human genomic DNA fragments that hybridized to the GlcAT-I cDNA probe were subcloned into Bluescript plasmid vectors and sequenced.
Identification of the 5h end of GlcAT-I mRNA
The site of transcription initiation in human placenta was determined by using a Cap site cDNA TM kit (Wako, Osaka, Japan) in accordance with the manufacturer's instructions. The kit is based on a method that consists of removing the cap with tobacco acid pyrophosphatase and ligating an oligoribonucleotide to decapped mRNA species with T4 RNA ligase [12] . The first PCR with an anti-sense primer, 5h-ATCCTTCTGCCGT-AGCTGCTC-3h (the nucleotide sequence corresponding to 124-144 ; see Figure 1 in [6] ), and an anchor primer (1RC) provided by the manufacturer was followed by nested PCR with an anti-sense primer, 5h-TTGCAGCTGGGAAATCCTCAG-3h (the nucleotide sequence corresponding to 145-165 ; see Figure 1 in [6] ), and an anchor primer (2RC) also provided by the manufacturer. For each reaction, 35 cycles (94 mC for 30 s, 55 mC for 30 s, 72 mC for 45 s) were run with EX Taq polymerase (Takara Shuzo Co., Kyoto, Japan) in 5 % (v\v) DMSO. The final PCR products were subcloned into pGEM2-T Easy vector (Promega, Tokyo, Japan) and sequenced in a 377 DNA sequencer (PE Applied Biosystems, Foster City, CA, U.S.A.). Several clones were sequenced to compensate for misreading by EX Taq polymerase.
Northern blot analysis
A commercial human Multiple Tissue Northern Blot I membrane (ClonTech, Tokyo, Japan) was used for the analysis ; 2 µg of polyadenylated RNA was loaded in each lane. The membrane was probed with a gel-purified, radiolabelled (more than 10* c.p.m.\µg), human GlcAT-I cDNA fragment of 1.4 kb [6] .
Functional analysis of the promoter
A 1230 bp GlcAT-I promoter region, which contained the 1198 bp sequence upstream of the transcription initiation site and the 32 bp exon I 5h sequence, was amplified by PCR with the sense primer 5h-CTAGCTAGCGCGCCCAGCTGCTAACA-GCA-3h (the nucleotide sequence corresponding to k1198 to k1179 ; see Figure 5 ), and the anti-sense primer 5h-CCCAA-GCTTGCGAGAAACACGTTCTTAGC-3h (the nucleotide sequence corresponding to 12-32 ; see Figure 5 ), with the GlcAT-I genomic clone (C1) as a template. In addition, various lengths of the GlcAT-I promoter region were amplified by PCR with one of the sense primers 5h-CTAGCTAGCGGACACAAAACTG-CCCTGTGGC-3h (the nucleotide sequence corresponding to k604 to k583 ; see Figure 5 ), 5h-CTAGCTAGCTTTTGACT-GCCGGCCACGC-3h (the nucleotide sequence corresponding to k303 to k285 ; see Figure 5 ) or 5h-CTAGCTAGCCAGC-TGGGAGCTGGTAGGGGA-3h (the nucleotide sequence corresponding to k153 to k131 ; see Figure 5 ) and the anti-sense primer shown above, with the GlcAT-I genomic clone (C1) as a template. NheI and HindIII restriction sites were introduced at the 5h ends of the sense and anti-sense primers respectively. Each PCR product was digested with NheI and HindIII and then subcloned into a pGL3-Basic luciferase reporter vector (Promega). The presence of the correct insert was confirmed by direct sequencing. Each construct was mixed with the pRL-TK vector (Promega) and these were transfected into cells on 60 mm plates with FuGENE TM 6 (Roche Molecular Biochemicals, Tokyo, Japan) in accordance with the manufacturer's instructions. The pRL-TK vector, which contains the thymidine kinase promoter from herpes simplex virus and the Renilla luciferase reporter gene, was used as an internal control to normalize for the efficiency of the transient transfection. After 48 h the luciferase activity was assayed with the dual luciferase reporter assay system (Promega). As a control we used an empty firefly luciferase vector (pGL3-Basic) and a pGL3-Control vector (Promega) in which the firefly luciferase expression is driven by the simian virus 40 (SV40) promoter\enhancer.
In situ chromosome hybridization
In situ hybridization was performed on chromosome preparations obtained from phytohaemagglutinin-stimulated human lymphocytes cultured for 68-72 h. 5-Bromodeoxyuridine was added for the final 7 h of culture (0.18 mg\ml of medium) to synchronize the cell population. A 3.1 kb BglII genomic fragment containing exons I and II (see Figure 1 ) was used as the probe, which was biotinylated with dATP by using the BioNick labelling kit (Life Technologies, Gaithersburg, MD, U.S.A.). The procedure for fluorescence in situ hybridization (FISH) detection was performed as described previously [13, 14] . In brief, the chromosome slides were baked at 55 mC for 1 h. After RNase treatment, the slides were treated in 70 % formamide in 2iSSC for 2 min at 70 mC to denature the chromosomes followed by dehydration with ethanol. The probes were denatured in a hybridization mixture consisting of 50 % (v\v) formamide and 10 % (w\v) dextran sulphate at 75 mC for 5 min. The probes were loaded on the denatured chromosomal slides. After hybridization overnight, slides were washed and signals were detected and amplified with the published method [13] . FISH signals and the 4,6-diamidino-2-phenylindole (DAPI) banding pattern were recorded separately by taking photographs ; the assignment of the FISH mapping data with chromosomal bands was achieved by superimposing FISH signals on DAPI-banded chromosomes [14] .
RESULTS

Isolation of GlcAT-I and determination of the exon/intron structure
Previously we identified a 1005 bp open reading frame in a 1.47 kb human GlcAT-I cDNA [6] . To determine the genomic 
Table 1 Exons of human GlcAT-I
For each exon the cDNA residues and positions of the amino acid sequence predicted by the open reading frame are given as numbered in Figure 1 in [6] .
Exon number
Exon length (bp) structure of the human GlcAT-I gene, we screened a human placenta genomic library with the cloned GlcAT-I cDNA fragment and found three independent clones, C1-C3. Insert DNA fragments were characterized by restriction digestion and Southern blot analysis. Sequencing revealed that the two clones (C1 and C2) overlapped each other and contained all exons corresponding to human GlcAT-I cDNA. As summarized in Figure 1 , the human GlcAT-I gene spanned approx. 7 kb and the coding sequence of GlcAT-I was divided into five exons. All exons contained the coding sequences indicated in Figure 1 . In addition, exon V contained the 3h untranslated region, which included the polyadenylation signal AATAAA. The locations of the GlcAT-I exons were determined by sequencing the genomic clones. Sequencing was also done to determine the exact size of the exons and the introns as shown in Table 1 and to determine the sequences of the intron\exon junctions as shown in Table 2 . All the intron\exon junctions followed the GT\AG rule and were flanked by conserved sequences [15] . The sequence encoded by these exons was identical with that of the human GlcAT-I cDNA [6] .
Identification of a pseudogene related to human GlcAT-I
The mapping data of the remaining clone, C3, was not consistent with that obtained for clones C1 and C2. A sequencing analysis of clone C3 revealed that it contained a related but distinct human GlcAT-I sequence. A sequence comparison between the GlcAT-I cDNA and the related clone, shown in Figure 2 , showed that they shared 95.3 % identity and the related sequence contained multiple nucleotide changes, insertions and deletions. These sequence alterations would cause a frameshift and nonsense mutations, which would prematurely terminate the translation of the potential GlcAT-I open reading frame that follows the translation initiation start codon located in the same relative position. These findings suggest that clone C3 contained a processed GlcAT-I pseudogene.
Figure 4 Northern blot analysis of GlcAT-I in human adult tissues
Northern blots with RNA from various human adult tissues were hybridized with a probe for GlcAT-I, as described in the Experimental section. The positions of size markers are indicated at the left.
Chromosomal mapping of GlcAT-I and the related pseudogene
By using a genomic fragment of GlcAT-I, in situ hybridization to normal metaphase chromosomes was performed to determine the chromosomal localization of the human gene. Of 100 metaphase cells examined by this hybridization, 61 showed signals on one pair of the long arms of chromosome 11. The detailed position was further determined on the basis of the summary of 10 photos (Figure 3 , upper panels). No additional locus was identified by FISH detection under the conditions used (see the Experimental section). These findings clearly indicate that GlcAT-I is located at human chromosome 11q12-q13 ( Figure  3 , lower panel). While this manuscript was in preparation, the database search of the Human Genome Project showed a human chromosome 11q12.2 sequence (accession number AC004230) that encompassed the GlcAT-I sequence and was consistent with the present findings. Notably, the database search also revealed that GlcAT-I was located downstream of the ROM1 gene encoding the retinal outer segment membrane protein 1 [16] and separated by an intergenic region of only 194 bp. The two genes are transcribed in opposite directions. In addition, a search of the unfinished high-throughput genomic sequence database identified a human chromosome 3 ' working draft ' sequence (accession number AC012057) identical with a GlcAT-I processed pseudogene sequence. Thus the GlcAT-I processed pseudogene has been mapped to chromosome 3.
Differential expression of GlcAT-I
To determine the size and expression pattern of the GlcAT-I mRNA in human tissues, Northern blot analysis of mRNA was performed ; the results demonstrated a single band of 1.5 kb for all human tissues examined (Figure 4) . However, expression of the mRNA varied considerably, exhibiting a unique tissuespecific pattern of expression. These differential expression patterns have also been described in mouse tissues [10] .
Promoter region of GlcAT-I
The 5h-flanking region of exon I of the GlcAT-I gene was sequenced to study the putative promoter region ( Figure 5 ). The
Figure 5 Nucleotide sequences of the human GlcAT-I promoter
The two putative start sites of transcription are shown by bent arrows. The consensus binding sites for the transcription factors are underlined. The sequences are numbered relative to the translation initiation site ATG, which is boxed. transcription initiation site in RNA from human placenta was determined by using the Cap site cDNA TM kit as described in the Experimental section. Two putative start sites were found and located at positions k37 and k29 (relative to A +" TG) in GlcAT-I ( Figure 5 ). The sum total (1.47 kb) of the revealed exon sequences was consistent with the size of the GlcAT-I mRNA, which was estimated to be 1.5 kb by Northern analysis (see Figure 4) . Analysis of 1.2 kb of the 5h-flanking region revealed that the region has a subregion with high GjC content (70 % in the 400 bp proximal region ; see Figure 5 ) and four potential Sp1-binding sites, which are present in many constitutive gene promoters. Although the region lacks canonical TATA or CCAAT boxes, there are two potential TATA boxes (at k801 and k1177 bp in Figure 5 ) and one potential CCAAT box (at k464 bp in Figure 5 ) upstream of the GC-rich region. In addition, the 5h-flanking region contains many other well characterized promoter elements, as shown in Figure 5 . These include response elements for SRY (sex-determining region Y gene product) [17] , Ets [18] , MZF-1 (myeloid zinc-finger protein) [19] , AML-1a (acute myeloid leukaemia gene product) [20] , Lyf-1
Figure 6 Functional analysis of the human GlcAT-I promoter
Luciferase expression assays with the GlcAT-I promoter construct containing a 1230 bp GlcAT-I promoter region (see Figure 5) were performed in four different cultured human cells. Firefly luciferase activity was assayed as described in the Experimental section and is expressed as a percentage of that produced by the pGL3-Control vector containing the SV40 promoter/ enhancer. Values were normalized for transfection efficiency on the basis of the Renilla luciferase value recorded in the same cells. Values are normalized means for three separate assays, each conducted in quadruplicate. The S.D. of the quadruplicates and of separate assays was less than 10 %.
(lymphocytes-specific factor) [21] , AP-1 (activator protein 1) [22] , GATA-1 [23] , Nkx-2.5 (tinman homeodomain factor) [24] , CDP CR3jHD (cut-like homeodomain protein) [25] , c-Rel [26] , Oct-1 (octamer factor) [27] , deltaEF1 (delta-crystallin enhancerbinding protein) [28] , USF (upstream stimulatory factor) [29] , NMyc [30] , CREB (cAMP-response-element-binding protein) [31] , STAT (signal transducers and activators of transcription) [32] and p300 (E1A-associated 300 kDa protein) [33] . Three putative binding sites for products of the Ets family were located close to the transcription initiation sites because, in a number of promoters lacking a canonical TATA box, Ets motifs are reported to be located close to the transcription initiation sites [18] .
Promoter analysis of GlcAT-I
Next we sought to determine whether the 5h-flanking region of GlcAT-I could act as a functional promoter in transient celltransfection assays. For this purpose a 1230 bp genomic fragment containing the 1198 bp sequence upstream of the transcription initiation site and the 32 bp exon I 5h sequence was cloned upstream of a firefly luciferase reporter gene in a pGL3 vector, as described in the Experimental section. This construct was transfected into four different cultured human cells along with a Renilla luciferase reporter gene driven by a thymidine kinase promoter from herpes simplex virus to normalize for transfection efficiency. The pGL3-Control vector, in which the firefly luciferase expression is driven by the SV40 promoter\enhancer, was used as a positive control. As shown in Figure 6 , in all four cell lines examined the GlcAT-I promoter displayed high and comparable activity to that of the SV40 promoter, demonstrating the promoter activity of the 5h-flanking region of GlcAT-I. In particular, the highest promoter activity was detected in G361 melanoma cells. Expression in HepG2 hepatoma cells was approximately one-third of that detected in G361 cells. These findings provide evidence for the differential regulation of the gene expression as observed above (see Figure 4) .
Further experiments with the most responsive G361 melanoma cells were performed to investigate the functional role of the cisacting elements. For this purpose, stepwise deletions of the GlcAT-I promoter were generated ( Figure 7) . The highest level of promoter activity was observed with the construct containing the sequence from k303 to j32 (Figure 7) . Shortening of the upstream sequence from k1198 to k304 slightly increased the promoter activity, suggesting that this region might contain negative regulatory sequences. Remarkably, deletion of the sequence from k303 to k154, which harbours one CREB, one STAT and three Ets motifs, caused a sharp decrease in functional promoter activity. The relative proximity of these three cis-acting elements suggests that this region might act as a functional domain.
DISCUSSION
Here we present the isolation and characterization of a functional human GlcAT-I and a GlcAT-I-related pseudogene. The findings obtained indicated that the human genome contains two related GlcAT-I genes, at chromosomes 11q12-q13 and 3. Only the 11q12-q13 locus is a functional human GlcAT-I ; the other is non-functional and seems to be a processed pseudogene that remains permanently silent.
The functional GlcAT-I spans 7 kb and consists of five exons. GlcAT-I, like other Golgi-resident glycosyltransferases, is composed of a short N-terminal cytoplasmic domain, a transmembrane domain, a stem region and a large catalytic domain [6] . Exon I encodes the nucleotide sequence corresponding to both the cytoplasmic and transmembrane domains ; exon II and exons III-V mainly encode the nucleotide sequences corresponding to the stem region and the large catalytic domain respectively. We recently determined the crystal structure of human GlcAT-I in the presence of the donor substrate product UDP, the catalytic Mn# + ion and the acceptor substrate analogue Galβ1-3Galβ1-4Xyl [34] . The findings revealed that the enzyme is an α\β protein with two subdomains that constitute the donor and acceptor substrate-binding sites and that the active site residues lie in a cleft extending across both subdomains. From both this observation and the present analysis of the intron\exon structure of GlcAT-I, it became apparent that one subdomain containing the donor substrate-binding site was encoded by exon III, whereas the other subdomain containing the acceptorbinding site and the catalytic base was encoded by exons IV and V.
As described previously [6] , the amino acid sequence of GlcAT-I exhibits 42.7 % identity with rat GlcAT-P involved in the biosynthesis of the carbohydrate epitope HNK-1 ; the highest sequence identity was found in the C-terminal catalytic domain containing the four previously identified highly conserved motifs (I-IV) [7] . It should be noted that each of the highly conserved motifs I, II and IV is divided into two exons in GlcAT-I. However, it is not surprising that a molecular similarity exists between the two enzymes, although the product glycan types are different (the GAG linkage region and the HNK-1 epitope on Nlinked glycoproteins), because the two enzymes exhibit a certain similarity in their substrate recognition (both enzymes recognize the terminal galactose moiety of their acceptor substrates). Very recently, cDNA cloning and chromosomal mapping of human GlcAT-P have been reported [35] . Human GlcAT-P is highly similar (98.2 % identity) to the rat counterpart ; human GlcAT-P was mapped to chromosome 11q25. Therefore, although the genomic structure of the GlcAT-P gene has not yet been reported, the two human β1,3-glucuronyltransferases GlcAT-I and GlcAT-P show molecular similarity and these genes are located on the same chromosome, 11q, suggesting that both genes might be evolutionarily related and originate from one primordial gene.
Interestingly, human GlcAT-I is located downstream of human ROM1 encoding retinal outer segment membrane protein 1 [16] and separated by an intergenic region of only 194 bp. Thus the two genes are contiguous in the human genome in a tail-to-tail manner. Rom-1 is reported to be required for mammalian rod photoreceptor viability and the regulation of disk morphogenesis ; it has been suggested that mutations in human ROM1 might cause recessive photoreceptor degeneration [36] . In addition, these two genes are also contiguous in the mouse genome (Y. Tone, H. Kitagawa and K. Sugahara, unpublished work). Although the two genes seem to be functionally unrelated and are transcribed independently, they might be also contiguous in other mammalian genomes.
In addition to the functional gene, the human genome contained another homologous GlcAT-I gene corresponding to a processed pseudogene. Analysis of this pseudogene sequence revealed several interesting features, which are common to many previously characterized processed pseudogenes (reviewed in [37] ). The pseudogene lacks completely the intervening sequences found in the functional gene. The existence of multiple nucleotide changes and a deletion event in the putative coding region indicate clearly that this gene is not functional. The pseudogene contains an insignificantly sized open reading frame, as it is capable of encoding only a 45-residue polypeptide. Although the GlcAT-I pseudogene contains a 3 bp insertion in the putative 5h untranslated region and has a 10 bp deletion in the putative coding region, it has retained high sequence identity (95.3 %) with human GlcAT-I cDNA, suggesting that the pseudogene was formed recently in evolutionary time, perhaps during the descent of Homo sapiens. In fact, there is no GlcAT-I pseudogene in the mouse genome (Y. Tone, H. Kitagawa and K. Sugahara, unpublished work). In addition, the sequence similarity between the pseudogene and the functional gene ceases at the points corresponding to the beginning and the end of the transcript from the functional gene (see Figure 2) . Furthermore, the pseudogene has a poly(A) sequence immediately 3h of the point at which the similarity between the pseudogene and the functional gene ceases. Lastly, the chromosomal locations of the human GlcAT-I pseudogene and the corresponding functional gene are not syntenic, in that the pseudogene is localized to chromosome 3 and the functional gene to chromosome 11q12-q13. All these features clearly indicate that the pseudogene was derived from the mature GlcAT-I mRNA and is a processed pseudogene.
As shown in the present study, the GlcAT-I promoter was differentially active in the cell lines tested, exhibiting 3-fold higher activity in G361 cells, a melanoma cell line that expresses this gene highly, compared with HepG2 cells, a hepatoma cell line that expresses this gene moderately (Y. Tone, H. Kitagawa and K. Sugahara, unpublished work). These findings seem to support the differential regulation of GlcAT-I expression. In addition, the activity of the GlcAT-I promoter was comparable to that of the SV40 promoter. In this regard it should be noted that transfection of GlcAT-I cDNA into COS cells induced the expression of the HNK-1 epitope when the vectors were used under the control of a strong promoter, although GlcAT-I shows strict specificity for the GAG-protein linkage region trisaccharide Galβ1-3Galβ1-4Xyl, exhibiting negligible incorporation into other galactoside substrates [9, 10] . It is therefore possible that in tissues that strongly express the GlcAT-I gene the HNK-1 epitope GlcA(3-O-sulphate)β1-3Galβ1-4GlcNAc is synthesized, because the HNK-1 3-O-sulphotransferase is widely distributed in various tissues [38, 39] . In fact, G361 cells highly express the HNK-1 epitope (M. Taoka, H. Kitagawa and K. Sugahara, unpublished work). Hence, at certain specific developmental stages or under pathological conditions including cancers, GlcAT-I might participate in the synthesis of the HNK-1 epitope. Interestingly, in this context, a deletion analysis of the GlcAT-I promoter with G361 cells revealed that the minimum promoter region contained potential binding sites for tissue-specific transcription factors such as STAT, CREB or Ets. In particular, the Ets family of transcription factors is reported to be related to transformation, signal transduction and cell differentiation (reviewed in [40] ). Moreover, Bai et al. [8] reported that transfection of Chinese hamster ovary cell mutants defective in GlcAT-I with GlcAT-I cDNA augmented GAG synthesis to levels approximately double those in wild-type cells, implying that GlcAT-I might be ratelimiting. It is therefore of particular importance to elucidate the tissue-specific regulatory mechanism of GlcAT-I expression. More detailed functional analysis of the promoter is now in progress.
